welcome Welcome

“May all be happy, may all be healed, may all be at peace and may no one ever suffer."


Ziska Pharmaceuticals Ltd.

Green City Edge, 89 Kakrail C/A, Dhaka Dakshin, Dhaka
info@ziskapharma.com
...
Ziska Pharmaceuticals Ltd.
Loading...

Paloron ODT 0.5mg

Size: 30 Price: 660.00
Orally Dispersible Tablet Orally Dispersible Tablet
Palonosetron
Anti-emetic drugs
0.00 (0)



Alternate Strengths


Generic for Diseases

Generic Indications
  • Chemotherapy-induced nausea and vomiting
  • Nausea and vomiting
  • Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy
  • Post-operative nausea and vomiting

Generic Description

Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors that are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema, to initiate the vomiting reflex. Postoperative nausea and vomiting is influenced by multiple patient, surgical and anesthesia related factorcs and is triggered by release of 5-HT3 in a cascade of neuronal event involving both the central nervous system and the gastrointestinal tract. The 5-HT3 receptor has been demonstrated to selectively participate in the emetic response. Palonosetron works by blocking the actions of Serotonin, associated with nausea and vomiting, at 5-HTs receptor. It is likely that Palonosetron works in the small intestine but it may also work in the brain.

Pharmacokinetics: Palonosetron exhibits linear dose-proportional pharmacokinetics over the doserange 1-90 pg/kg in healthy subjects and in patients with cancer. In cancer patients receiving single intravenous doses of Palonosetron in this dose range, the mean maximum plasma concentration (Cmax) ranges from 0.89 to 336 ng/ml and the area under the plasma concentration-time curve from zero to infinity (AUCo-co) ranges from 13.8 to 957 ng.h/ml. Palonosetron has a volume of distribution of approximately 6.9-7.9 L/kg, with approximately 62% bound to plasma proteins. Approximately 50% of Palonosetron is metabolized into two inactive metabolites that exhibit <1% of the 5-HT3 receptor antagonist activity. Approximately 40% of the drug is metabolised via kidney, 50% by liver CYP2D6 (mainly), CYP3A4 and CYP1A2 isoenzymes. About 50% of the drug goes under metabolism. After a single intravenous dose, approximately 40% is excreted as unchanged drug in the urine after 144 hours. Total body clearance of Palonosetron is 160±35 ml/h/kg, and renal clearance is 66.5±18.2 ml/h/kg in healthy subjects. Palonosetron exhibits a longer half-life (40 hours) and has a greater 5-HT3 receptor binding affinity.


Component

Drug Indication

Palonosetron indicated in-

  • Acute and delayed nausea and vomiting
  • Uncontrolled nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Acute CINV resulting in on the day of treatment with certain types of chemotherapy
  • Delayed CINV resulting in on days later with certain types of chemotherapy
  • Radiotherapy-induced nausea and vomiting (RINV)
  • Post-operative & Post-discharge nausea and vomiting (PONV & PDNV).

Dosage Administration

Usual dosage: Adult tablet dosage: 0.5 mg daily. Adult IV dosage: A single IV dose of 0.075 mg should be administered over 10 seconds.

Chemotherapy-induced nausea and vomiting: Adult tablet dosage: 0.5 mg administered approximately 1 hour prior to the start of chemotherapy. Adult IV dosage: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before the start of chemotherapy.

Radiotherapy-induced nausea and vomiting: A single IV dose of 0.25 mg should be administered over 30 seconds approximately 30 minutes before each week of radiation fraction.

Post-operative nausea and vomiting: A single IV dose of 0.075 mg should be administered over 10 seconds immediately before induction of anesthesia.

Children dosage: (1 month to 17 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.


Contraindication

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components.


Side Effect

The most common adverse reactions are headaches and constipation.

Overdose Effects

There is no known antidote to Palonosetron. Overdose should be managed with supportive care.


Precaution Warning

Pregnancy & Lactation

Pregnancy category 'B'. It is not known whether Palonosetron is excreted in breast milk.

Use in Special Populations

Use in elderly patients: No dosage adjustment is recommended in elderly patients >65 years of age.

Use in Children: (1 month to 10 years): A single IV dose at 20 mcg/kg body weight. Which maximum dose is 1.5 mg.

Use in patients with impaired renal and hepatic function: No dosage adjustment is recommended in patients with renal and hepatic dysfunction.





Store

Paloron ODT 0.5mg and more Available Brands


...
Rotate 400mg
Calcium Orotate
Tablet
S: 30 , P: 150.00
...
Ziskavit-M
Multivitamin [Adult Preparation]
Tablet
S: 30 , P: 60.00
...
Zincoral DT 20mg
Zinc Sulfate Monohydrate
OD Tablet
S: 100 , P: 200.00
...
Vitilen 10mg
Methoxsalen
Capsule
S: 50 , P: 500.00
...
Analac 60mg / 2ml
Ketorolac Tromethamine
IM/IV Injection
S: 2 ml ampoule , P: 95.00
...
Rifaxin 550mg
Rifaximin
Tablet
S: 8 , P: 360.00
...
Terbitac 250mg
Terbinafine Hydrochloride
Tablet
S: 10 , P: 500.00
...
Analac 30mg / ml
Ketorolac Tromethamine
IM/IV Injection
S: 5 (1 ml ampoule) , P: 275.00

Searching Keywords Idea
...

Bangladesh is Number One in Digital Medical Management.
To be happy, beautiful, healthy, wealthy, hale and long-lived stay with DM3S.